Lexaria Price To Sales Ratio vs Ptb Ratio Analysis

LEXXW Stock  USD 0.55  0.05  8.33%   
Lexaria Bioscience financial indicator trend analysis is infinitely more than just investigating Lexaria Bioscience Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lexaria Bioscience Corp is a good investment. Please check the relationship between Lexaria Bioscience Price To Sales Ratio and its Ptb Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Price To Sales Ratio vs Ptb Ratio

Price To Sales Ratio vs Ptb Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lexaria Bioscience Corp Price To Sales Ratio account and Ptb Ratio. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Lexaria Bioscience's Price To Sales Ratio and Ptb Ratio is -0.08. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Ptb Ratio in the same time period over historical financial statements of Lexaria Bioscience Corp, assuming nothing else is changed. The correlation between historical values of Lexaria Bioscience's Price To Sales Ratio and Ptb Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Lexaria Bioscience Corp are associated (or correlated) with its Ptb Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ptb Ratio has no effect on the direction of Price To Sales Ratio i.e., Lexaria Bioscience's Price To Sales Ratio and Ptb Ratio go up and down completely randomly.

Correlation Coefficient

-0.08
Relationship DirectionNegative 
Relationship StrengthInsignificant

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Lexaria Bioscience Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Lexaria Bioscience sales, a figure that is much harder to manipulate than other Lexaria Bioscience Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.
Most indicators from Lexaria Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lexaria Bioscience Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
At this time, Lexaria Bioscience's Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to climb to 415.56 in 2025, whereas Selling General Administrative is likely to drop slightly above 2.5 M in 2025.
 2024 2025 (projected)
Other Operating Expenses7.2M7.5M
Interest Expense102.9K125.2K

Lexaria Bioscience fundamental ratios Correlations

0.60.350.990.01-0.89-0.710.640.960.20.960.570.240.310.710.810.280.210.96-0.58-0.23-0.450.44-0.23-0.60.46
0.60.450.56-0.2-0.46-0.70.980.580.00.550.550.410.550.940.80.350.020.61-0.38-0.290.120.01-0.31-0.560.8
0.350.450.210.770.08-0.110.510.10.850.09-0.20.290.380.330.20.970.860.11-0.460.390.190.140.380.070.32
0.990.560.21-0.11-0.94-0.730.590.990.080.990.620.210.260.690.820.150.090.99-0.55-0.3-0.510.43-0.31-0.640.43
0.01-0.20.77-0.110.380.33-0.1-0.250.97-0.24-0.560.050.07-0.28-0.280.80.96-0.26-0.240.650.10.190.650.42-0.18
-0.89-0.460.08-0.940.380.7-0.46-0.970.22-0.98-0.68-0.12-0.14-0.61-0.750.120.21-0.970.410.430.52-0.350.430.68-0.39
-0.71-0.7-0.11-0.730.330.7-0.69-0.720.11-0.7-0.86-0.25-0.63-0.84-0.97-0.090.11-0.750.340.570.44-0.380.60.69-0.4
0.640.980.510.59-0.1-0.46-0.690.590.090.560.50.470.560.950.80.420.120.62-0.45-0.220.110.0-0.24-0.560.81
0.960.580.10.99-0.25-0.97-0.720.59-0.071.00.660.190.220.710.810.04-0.051.0-0.49-0.36-0.460.37-0.36-0.680.48
0.20.00.850.080.970.220.110.09-0.07-0.07-0.370.130.21-0.06-0.050.850.99-0.07-0.350.560.020.280.560.26-0.05
0.960.550.090.99-0.24-0.98-0.70.561.0-0.070.650.180.20.680.80.03-0.051.0-0.49-0.36-0.490.38-0.36-0.670.45
0.570.55-0.20.62-0.56-0.68-0.860.50.66-0.370.650.070.460.660.84-0.25-0.40.680.08-0.77-0.280.46-0.8-0.570.2
0.240.410.290.210.05-0.12-0.250.470.190.130.180.070.230.450.310.240.150.21-0.35-0.190.04-0.3-0.18-0.010.28
0.310.550.380.260.07-0.14-0.630.560.220.210.20.460.230.530.590.410.20.25-0.12-0.26-0.070.28-0.31-0.30.22
0.710.940.330.69-0.28-0.61-0.840.950.71-0.060.680.660.450.530.910.23-0.040.74-0.49-0.4-0.130.05-0.41-0.670.73
0.810.80.20.82-0.28-0.75-0.970.80.81-0.050.80.840.310.590.910.13-0.050.84-0.41-0.51-0.380.35-0.53-0.710.52
0.280.350.970.150.80.12-0.090.420.040.850.03-0.250.240.410.230.130.860.05-0.430.410.160.170.40.110.23
0.210.020.860.090.960.210.110.12-0.050.99-0.05-0.40.150.2-0.04-0.050.86-0.06-0.420.58-0.010.220.580.23-0.02
0.960.610.110.99-0.26-0.97-0.750.621.0-0.071.00.680.210.250.740.840.05-0.06-0.49-0.39-0.460.38-0.39-0.690.48
-0.58-0.38-0.46-0.55-0.240.410.34-0.45-0.49-0.35-0.490.08-0.35-0.12-0.49-0.41-0.43-0.42-0.49-0.260.550.14-0.280.48-0.47
-0.23-0.290.39-0.30.650.430.57-0.22-0.360.56-0.36-0.77-0.19-0.26-0.4-0.510.410.58-0.39-0.260.21-0.181.00.090.17
-0.450.120.19-0.510.10.520.440.11-0.460.02-0.49-0.280.04-0.07-0.13-0.380.16-0.01-0.460.550.21-0.250.180.430.2
0.440.010.140.430.19-0.35-0.380.00.370.280.380.46-0.30.280.050.350.170.220.380.14-0.18-0.25-0.2-0.06-0.22
-0.23-0.310.38-0.310.650.430.6-0.24-0.360.56-0.36-0.8-0.18-0.31-0.41-0.530.40.58-0.39-0.281.00.18-0.20.120.15
-0.6-0.560.07-0.640.420.680.69-0.56-0.680.26-0.67-0.57-0.01-0.3-0.67-0.710.110.23-0.690.480.090.43-0.060.12-0.68
0.460.80.320.43-0.18-0.39-0.40.810.48-0.050.450.20.280.220.730.520.23-0.020.48-0.470.170.2-0.220.15-0.68
Click cells to compare fundamentals

Lexaria Bioscience Account Relationship Matchups

Lexaria Bioscience fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets13.3M7.8M3.1M8.9M10.2M10.7M
Other Current Liab45K51.7K239.9K1.1M1.2M1.3M
Total Current Liabilities153.3K194.0K267.7K1.1M989.5K1.0M
Total Stockholder Equity13.3M7.9M3.0M8.0M9.2M9.7M
Property Plant And Equipment Net459.3K367.9K421.6K389.6K350.6K333.1K
Net Debt(10.8M)(5.8M)(1.2M)(6.4M)(5.7M)(5.4M)
Retained Earnings(31.8M)(39.1M)(45.8M)(51.6M)(46.4M)(44.1M)
Accounts Payable59.9K25.8K225.0K1.1M1.2M1.3M
Cash10.9M5.8M1.4M6.5M7.5M7.8M
Non Current Assets Total823.9K856.4K884.2K969.8K872.8K1.3M
Cash And Short Term Investments11.8M6.2M1.5M6.6M7.5M7.9M
Common Stock Shares Outstanding4.4M5.9M6.6M12.4M14.2M15.0M
Liabilities And Stockholders Equity13.3M7.8M3.1M8.9M10.2M10.7M
Non Current Liabilities Total50.0K7.4K136.2K109.3K98.4K93.5K
Other Current Assets319.3K576.8K546.8K1.2M1.4M1.4M
Other Stockholder Equity45.1M47.0M48.8M59.6M68.6M72.0M
Total Liab203.3K201.4K403.9K1.2M1.1M577.9K
Property Plant And Equipment Gross483.4K773.2K747.9K896.8K807.1K1.4M
Total Current Assets12.4M7.0M2.2M7.9M9.1M9.5M
Common Stock90.0K5.7K6.0K8.1K9.3K8.8K
Short Long Term Debt Total97.3K50.0K164.0K137.4K123.6K117.4K
Net Receivables342.4K201.8K175.2K154.5K177.6K166.2K
Short Term Debt47.3K85.2K27.8K28.0K25.2K24.0K
Inventory116.9K29.6K38.4K1.00.90.86
Non Currrent Assets Other(823.9K)(856.4K)(884.2K)63.6K73.1K76.8K
Intangible Assets364.6K488.5K462.6K516.7K594.2K623.9K
Net Invested Capital2.6M13.3M7.9M3.0M3.5M5.4M
Net Working Capital1.7M12.3M6.8M1.9M2.2M2.1M
Short Term Investments833.8K347.3K125.6K55.8K64.2K61.0K
Capital Stock90.0K5.7K6.0K8.1K7.3K6.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.